Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma

Cancer

Volumn 101, Issue 7, 2004, Pages 1490-1500

  Chen, Wendy Y ^a,b,e   Hankinson, Susan E ^b,c   Schnitt, Stuart J ^d   Rosner, Bernard A ^b   Holmes, Michelle D ^b   Colditz, Graham A ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e CHANNING LABORATORY   (United States)

Author keywords

Breast carcinoma; Epidemiology; Estrogen receptor; Hormone replacement therapy; Progesterone receptor

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; METHYLTESTOSTERONE; PIPERAZINE ESTRONE SULFATE; PROGESTERONE; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER RISK; COHORT ANALYSIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

ADULT; BREAST NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 4844228689     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20499     Document Type: Article

References (44)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer [see comments]. Lancet. 1997;350:1047-1059. Erratum in: Lancet. 1997;350:1484.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer [see comments]. Lancet. 1997;350:1047-1059. Erratum in: Lancet. 1997;350:1484.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
4. Lower EE, Blau R, Gazder P, Stahl DL. The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer. Breast Cancer Res Treat. 1999;58:205-211.
5. Gajdos C, Tartter PI, Babinszki A. Breast cancer diagnosed during hormone replacement therapy. Obstet Gynecol. 2000; 95:513-518.
6. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287:734-741.
7. Ursin G, Tseng CC, Paganini-Hill A, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol. 2002;20:699-706.
8. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol. 2003;21:4314-4321.
9. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat. 1996;38:325-334.
10. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol. 1998;16:3115-3120.
11. Bilimoria MM, Winchester DJ, Sener SF, Motykie G, Sehgal UL, Winchester DP. Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics [see comments]. Ann Surg Oncol. 1999;6:200-207.
12. Fowble B, Hanlon A, Freedman G, et al. Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. J Clin Oncol. 1999;17:1680-1688.
13. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women [see comments]. N Engl J Med. 1995;332:1589-1593.
14. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
15. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 2000;152:950-964.
16. Ross RK, Paganinin-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92: 328-332.
17. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283:485-491.
18. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol. 1994;140:1016-1019.
19. Colditz GA, Stampfer MJ, Willett WC, et al. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol. 1987;126:319-325.
20. Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the Surveillance, Epidemiology, and End Results database. J Clin Oncol. 2001;19:18-27.
21. Rockhill B, Colditz G, Rosner B. Bias in breast cancer analyses due to error in age at menopause. Am J Epidemiol. 2000;151:404-408.
22. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289:3243-3253.
23. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int J Cancer. 1999;81:339-344.
24. Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA. 1999;281:1632-1637.
25. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Long-cope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev. 1995;4:649-654.
26. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003; 361:296-300.
27. Potter JD, Cerhan JR, Sellers TA, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev. 1995;4:319-326.
28. Yoo KY, Tajima K, Miura S, et al. Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis. Am J Epidemiol. 1997;146: 307-314.
29. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol. 2000;151:703-714.
30. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003;289:1421-1424.
31. Tabar L, Fagerberg G, Chen H, Duffy S, Gad A. Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer. 1996;66:413-419.
32. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
33. Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst. 1999;91:264-270.
34. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001;19:3817-3827.
35. Hakama M, Holli K, Isola J, et al. Aggressiveness of screen-detected breast cancers. Lancet. 1995;345:221-224.
36. Kricker A, Farac K, Smith D, Sweeny A, McCredie M, Armstrong BK. Breast cancer in New South Wales in 1972-1995: tumor size and the impact of mammographic screening. Int J Cancer. 1999;81:877-880.
37. Ernst MF, Roukema JA, Coebergh IW, et al. Breast cancers found by screening: earlier detection, lower malignant potential or both? Breast Cancer Res Treat. 2002;76:19-25.
38. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002;11:601-607.
39. Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast. Philadelphia: Lippincott Williams & Wilkins, 2000.
40. International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2002;94:1054-1065.
41. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-983.
42. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat. 2003;78:105-118.
43. Gruvberger S, Ringner M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 2001;61:5979-5984.
44. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874.